Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic and Extraglycemic Goals in Type 2 Diabetes: A ClinicalImpact Curriculum

Get patient-specific guidance on GLP-1 RA options using this Interactive Decision Support Tool. Then, review commentaries, perspectives, and slides from a panel of experts.
Martin J. Abrahamson, MD, FACP
Zachary T. Bloomgarden, MD, MACE
Anne Peters, MD

ClinicalThought

In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.

Zachary T. Bloomgarden, MD, MACE Physicians: maximum of 0.4 AMA PRA Category 1 Credits Registered Nurses: 0.4 Nursing contact hours Released: March 2, 2020 Expired: March 1, 2021

When discussing GLP-1 receptor agonists for patients with type 2 diabetes, it is important to know which adverse events may occur and which are myths.

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021

For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue